Is Eli Lilly and Company a good investment? Eli Lilly and Company (LLYC.VI) is currently trading at 706.40 EUR.
In terms of valuation, the stock trades at a P/E ratio of 131.06. This high multiple suggests investors have priced in significant future growth expectations.
Earnings Schedule: Eli Lilly and Company is expected to release its next earnings report on April 30, 2024.
For income investors, Eli Lilly and Company pays a dividend yield of 0.65%. With a payout ratio of 78%, the dividend appears to be under pressure.
Yes, it pays an annual dividend of 4.75 EUR (0.65% yield).
Eli Lilly and Company is classified as a Stock.
The next earnings date is projected to be April 30, 2024. The company currently has a trailing EPS of 5.39.
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
| Year | Total Dividends |
|---|---|
| ▸2024 |
1.30 EUR
|
| Feb. 14, 2024 | 1.3000 |
| ▸2023 |
4.52 EUR
|
| Nov. 14, 2023 | 1.1300 |
| Aug. 14, 2023 | 1.1300 |
| May 12, 2023 | 1.1300 |
| Feb. 14, 2023 | 1.1300 |
| ▸2022 |
3.92 EUR
|
| Nov. 14, 2022 | 0.9800 |
| Aug. 12, 2022 | 0.9800 |
| May 13, 2022 | 0.9800 |
| Feb. 14, 2022 | 0.9800 |
| ▸2021 |
3.40 EUR
|
| Nov. 12, 2021 | 0.8500 |
| Aug. 12, 2021 | 0.8500 |
| May 13, 2021 | 0.8500 |
| Feb. 11, 2021 | 0.8500 |
| ▸2020 |
2.96 EUR
|
| Nov. 12, 2020 | 0.7400 |
| Aug. 13, 2020 | 0.7400 |
| May 14, 2020 | 0.7400 |
| Feb. 13, 2020 | 0.7400 |
| ▸2019 |
0.65 EUR
|
| Nov. 14, 2019 | 0.6450 |
Community Discussion